{"id":"NCT00723528","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","officialTitle":"A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-01","completion":"2010-03","firstPosted":"2008-07-28","resultsPosted":"2014-05-20","lastUpdate":"2014-05-20"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Placebo (CP)","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 45 mg (CP)","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 90 mg (CP)","otherNames":[]},{"type":"DRUG","name":"Placebo A (After CP)","otherNames":[]},{"type":"DRUG","name":"Placebo B (After CP)","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 45 mg (After CP)","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 90 mg (After CP)","otherNames":[]}],"arms":[{"label":"Placebo (CP)","type":"PLACEBO_COMPARATOR"},{"label":"Ustekinumab 45 mg (CP)","type":"ACTIVE_COMPARATOR"},{"label":"Ustekinumab 90 mg (CP)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo A (After CP)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo B (After CP)","type":"PLACEBO_COMPARATOR"},{"label":"Ustekinumab 45 mg (After CP)","type":"ACTIVE_COMPARATOR"},{"label":"Ustekinumab 90 mg (After CP)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275) compared with placebo in participants with moderate to severe plaque type psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With Greater Than or Equal to 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI) Score","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo (CP)","deltaMin":6.5,"sd":null},{"arm":"Ustekinumab 45 mg (CP)","deltaMin":59.4,"sd":null},{"arm":"Ustekinumab 90 mg (CP)","deltaMin":67.7,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=425&filename=CR015166_w28CSR.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=425&filename=CR015166_finalCSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":32},"commonTop":["Nasopharyngitis","Blood triglycerides increased","Blood creatine phosphokinase increased","Seasonal allergy","Eosinophil count increased"]}}